Tony Hagen is senior managing editor for The Center for Biosimilars®.
FDA Approves Adalimumab Biosimilar From Fujifilm Kyowa Kirin Biologics
July 8th 2020The FDA has approved Fujifilm Kyowa Kirin Biologics's Hulio adalimumab biosimilar, making it the sixth adalimumab biosimilar approved in the United States. However, none will be launched before 2023 because of the strength of AbbVie's exclusivity rights for Humira, the reference product. Hulio launched in Europe in 2018.
BPCIA in Crosshairs as Opponents File Arguments With High Court to End Health Law
June 26th 2020Republican opponents of the Affordable Care Act (ACA), led by the state of Texas, fired opening salvos in the Supreme Court case over the landmark law's constitutionality. If the entire law is thrown out, approval for biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) would disappear, too.
Doctors Manage Insulin Degludec-to-Glargine Transition Poorly, ADA Study Says
June 20th 2020There is much inconsistency in the way physicians transition patients from insulin degludec to insulin glargine upon hospital admission, leading to higher risk especially for patients with type 1 diabetes, according to a study presented at the American Diabetes Association 80th Scientific Sessions online conference.
Celltrion Biosimilar Shows Efficacy in DLBCL Combination
June 16th 2020A rituximab biosimilar developed by Celltrion Healthcare demonstrates safety and efficacy in patients with relapsed or refractory aggressive B-cell lymphoma, in findings presented at EHA25 Virtual, the annual meeting of the European Hematology Association.